CZ322894A3 - Pharmaceutical preparation for inhibiting physiological derangement connected with excess of tachykinin - Google Patents

Pharmaceutical preparation for inhibiting physiological derangement connected with excess of tachykinin Download PDF

Info

Publication number
CZ322894A3
CZ322894A3 CZ943228A CZ322894A CZ322894A3 CZ 322894 A3 CZ322894 A3 CZ 322894A3 CZ 943228 A CZ943228 A CZ 943228A CZ 322894 A CZ322894 A CZ 322894A CZ 322894 A3 CZ322894 A3 CZ 322894A3
Authority
CZ
Czechia
Prior art keywords
formula
excess
tachykinin
phenyl
disorders
Prior art date
Application number
CZ943228A
Other languages
Czech (cs)
English (en)
Inventor
Bruce Donald Gitter
William Henry Walker Lunn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CZ322894A3 publication Critical patent/CZ322894A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CZ943228A 1993-12-21 1994-12-19 Pharmaceutical preparation for inhibiting physiological derangement connected with excess of tachykinin CZ322894A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/168,484 US5492927A (en) 1993-12-21 1993-12-21 Non-peptide tachykinin receptor antagonists to treat allergy

Publications (1)

Publication Number Publication Date
CZ322894A3 true CZ322894A3 (en) 1995-09-13

Family

ID=22611677

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ943228A CZ322894A3 (en) 1993-12-21 1994-12-19 Pharmaceutical preparation for inhibiting physiological derangement connected with excess of tachykinin

Country Status (17)

Country Link
US (2) US5492927A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0668075A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH07215863A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR950016746A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1108096A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU701606B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2138457A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ322894A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT71336A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL112029A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO944911L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ270187A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH31382A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2146520C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW321602B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA27911C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA9410085B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5847007A (en) 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2719474B1 (fr) 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
EP0895781A3 (en) * 1994-10-20 1999-07-07 Eli Lilly And Company Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6545027B1 (en) * 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
DE69622472T2 (de) * 1995-06-07 2003-02-06 Eli Lilly And Co., Indianapolis Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
AU732473B2 (en) * 1996-01-29 2001-04-26 Eli Lilly And Company Methods of increasing sphincter competence
US6113876A (en) * 1996-01-29 2000-09-05 Eli Lilly And Company Methods of increasing sphincter competence
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
HU228426B1 (hu) 1996-07-24 2013-03-28 Warner Lambert Co Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
US6410565B1 (en) 1999-02-03 2002-06-25 Eli Lilly And Company α1-adrenergic receptor antagonists
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US6372440B2 (en) 1999-03-10 2002-04-16 Magnesium Diagnostics, Inc. Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
DE60021720T2 (de) 1999-05-04 2006-06-01 Strakan International Ltd. Androgen glykoside und die androgenische aktivität davon
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
WO2003101459A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
KR20050091058A (ko) * 2003-01-06 2005-09-14 와이어쓰 다발성 경화증을 치료하기 위한 에스트로겐 수용체 알파조절제의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
CA2123403C (en) * 1991-11-12 2002-02-05 Brian T. O'neill Acyclic ethylenediamine derivatives as substance p receptor antagonists
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
CN1058390C (zh) * 1993-10-15 2000-11-15 伊莱利利公司 苯并噻吩类化合物的用途
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
JPH09506898A (ja) * 1993-12-21 1997-07-08 イーライ・リリー・アンド・カンパニー 非ペプチドタキキニン受容体アンタゴニスト
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5462950A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y

Also Published As

Publication number Publication date
UA27911C2 (uk) 2000-10-16
RU94044671A (ru) 1996-10-10
AU701606B2 (en) 1999-02-04
PH31382A (en) 1998-10-29
CN1108096A (zh) 1995-09-13
AU8153994A (en) 1995-06-29
NO944911L (no) 1995-06-22
NO944911D0 (no) 1994-12-19
ZA9410085B (en) 1996-06-19
IL112029A0 (en) 1995-03-15
RU2146520C1 (ru) 2000-03-20
HUT71336A (en) 1995-11-28
NZ270187A (en) 1997-07-27
IL112029A (en) 1999-10-28
TW321602B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-12-01
US5492927A (en) 1996-02-20
HU9403676D0 (en) 1995-02-28
EP0668075A2 (en) 1995-08-23
EP0668075A3 (en) 1996-10-16
JPH07215863A (ja) 1995-08-15
US5525624A (en) 1996-06-11
KR950016746A (ko) 1995-07-20
CA2138457A1 (en) 1995-06-22

Similar Documents

Publication Publication Date Title
CZ322894A3 (en) Pharmaceutical preparation for inhibiting physiological derangement connected with excess of tachykinin
EP0630376B1 (en) Condensed indole derivatives as 5-ht4-receptor antagonists
CZ2002767A3 (cs) Sulfonylkarboxamidové deriváty, způsob jejich přípravy a jejich pouľití jako léčiv
SK283918B6 (sk) Substituované deriváty 1,2,3,4-tetrahydronaftalénu, spôsob ich prípravy, medziprodukty na ich prípravu, farmaceutické prípravky s ich obsahom a ich použitie
EP0582368A1 (en) Thienobenzodiazepine derivatives for treatment of CNS disorders
RU2328487C2 (ru) Производные тетрагидрохинолина, фармацевтическая композиция на их основе, их применение в качестве регуляторов фертильности
CN106831574B (zh) N-(1,2,3,4-四氢异喹啉基)-阿魏酰胺-o-烷基胺类化合物和应用
EP3063139A1 (en) Heterocyclic compound
US5491140A (en) Naphthyl tachykinin receptor antagonists to treat physiological conditions
RU2300532C2 (ru) Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция
JP2002536441A (ja) Ａβフィブリル形成の阻害剤としてのピペリジンおよびピペラジン誘導体
GB2120662A (en) New azepinoindoles, their production and pharmaceutical compositions containing them
CN106831573A (zh) (n‑1,2,3,4‑四氢异喹啉基)‑阿魏酰胺化合物、制备方法及其应用
CN117088837B (zh) 乙烯基吡喃酮类化合物及其在治疗阿尔茨海默病中的应用
CZ126295A3 (en) Derivative of glucopyranoside benzothiophene, process of its preparation and a pharmaceutical composition containing thereof
AU2114600A (en) Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors
RU2181047C2 (ru) Способ ингибирования состояний, ассоциированных с брадикинином
US5258384A (en) S-11-hydroxy-10-methylaporphine and its biologically active salt forms as 5HT1A inhibitors
JP3830378B2 (ja) アシルアミノシクロプロパン誘導体
NZ271972A (en) Condensed indole derivatives and medicaments
RU2058985C1 (ru) Производные индола, способ их получения и фармацевтическая композиция для лечения психических расстройств на их основе
HRP920778A2 (en) Novel 1-oxa-2-oxo-8-azaspiro74,5/ decane derivatives, pharmaceutical preparations containing them and process for the preparation thereof
TW202442225A (zh) 一種吲哚類化合物及其應用
CS209944B2 (en) Method of making the cyclododecan derivatives
HU213421B (en) New basic ethers, pharmaceutical compns. containing the said compds. and process for prepg. them